SCOTUS extends mifepristone access

The justices are currently weighing a challenge to the FDA's decision to ease restrictions on mifepristone, which has become the most common method of abortion in the U.S. The extension prevents a lower court ruling from taking effect that would have significantly curtailed nationwide access to the medication.

Women's health experts warn that a permanent restriction could have far-reaching consequences for reproductive care, particularly in states with limited clinical facilities.

The final decision by the conservative-majority court is expected to be a landmark ruling on federal regulatory authority and reproductive rights.